AstraZeneca contributes to global rescue effort for Haiti

Wednesday, 13 January 2010

AstraZeneca is contributing to the global rescue effort in the wake of Haiti’s devastating earthquake. We have donated antibiotic and respiratory medicines (Meronem, Pulmicort and Rhinocort) through US charity AmeriCares and through Health Partners International in Canada, cardiovascular, gastrointestinal and respiratory (Tenormin, Losec, Nexium, Bricanyl, Pulmicort Turbuhaler) medicines.

In addition to our initial donation of $160,000, we have now donated a further $340,000 to the British Red Cross Emergency Appeal. We have also committed an additional $500,000 to support a longer-term disaster recovery programme that will give the people of Haiti the help they need to re-build their lives and their communities. We are currently working with AstraZeneca colleagues in the region to identify appropriate projects and partners.

How collaborative working can achieve the right safety profile

AZ scientists Mark Anderton and Ray Finlay discuss their role in re-designing an oncology compound

Achieving the right balance of benefit-risk is crucial; our job is to identify, characterise and eliminate molecules with negative benefit-risk balance as early and as quickly as possible.

Read the latest post on LabTalk

Read the latest blogs from our scientists working in our oncology portfolio

Oncology_compound_shows_THM 30 May 2014

Oncology compound shows how collaborative working can achieve the right safety profile

Driving open innovation across Asia THM 22 May 2014

AstraZeneca is driving open innovation across Asia